NASDAQ:CGIX Cancer Genetics (CGIX) Stock Forecast, Price & News $0.21 -0.02 (-8.85%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$0.21▼$0.2150-Day Range$0.22▼$0.6952-Week Range$2.11▼$17.50Volume5,935 shsAverage Volume2.44 million shsMarket Capitalization$841,510.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesSocial MediaProfileChartCompetitorsHeadlinesSocial Media About Cancer Genetics (NASDAQ:CGIX) StockVyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.Read More Receive CGIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address CGIX Stock News HeadlinesMay 25, 2023 | msn.comUCLA researchers say genetic mutation could be key to treating fatal brain tumorsMay 25, 2023 | americanbankingnews.comCancer Genetics (NASDAQ:CGIX) Now Covered by Analysts at StockNews.comMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 18, 2023 | msn.comJunk genes may hold keys to cancer cure, CWRU researchers findMay 17, 2023 | americanbankingnews.comCancer Genetics (NASDAQ:CGIX) Receives New Coverage from Analysts at StockNews.comMay 16, 2023 | technews.tmcnet.comNew Study Shows CancerIQ Plus Point-of-Care Genetic Testing Improves Access to Precision PreventionMay 9, 2023 | americanbankingnews.comCancer Genetics (NASDAQ:CGIX) Coverage Initiated by Analysts at StockNews.comMay 8, 2023 | washingtonpost.comAsk a Doctor: Which cancers can be detected through genetic testing?May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 8, 2023 | markets.businessinsider.comGenome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer CareMay 2, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Cancer Genetics (NASDAQ:CGIX)April 27, 2023 | msn.comCalls for ban on insurance companies using genetic testing information as doctors warn it puts Kiwis at riskApril 12, 2023 | msn.comScientists say 'genetic clues' could lead to blood test tracking cancer growth in real timeApril 3, 2023 | foxnews.comAI testing of brain tumors can detect genetic cancer markers in less than 90 seconds, study findsMarch 31, 2023 | msn.comCanadian researchers find new gene mutation that could be linked to increased breast cancer riskMarch 30, 2023 | dailymail.co.ukCancerMarch 29, 2023 | foxnews.comNew breast cancer gene can predict likelihood of hereditary disease, study findsMarch 27, 2023 | nypost.com‘Holy grail’ of cancer detection predicts tumors a year before they form: breakthroughMarch 27, 2023 | msn.comGenetic testing: How four generations of a family have battled multiple cancersMarch 25, 2023 | msn.comSaliva: The Next Frontier In Cancer DetectionMarch 25, 2023 | news.yahoo.comHundreds call helpline over Orkney cancer geneMarch 23, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Cancer Genetics (NASDAQ:CGIX)March 13, 2023 | msn.comSan Diego Genetic Sequencing Pioneer Illumina Fends Off Carl Icahn Proxy BidMarch 5, 2023 | benzinga.comPROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCERMarch 1, 2023 | usnews.comIs Obesity Especially Dangerous for Women at Genetic Risk for Breast Cancer?March 1, 2023 | marketwatch.comLatest Research on Breast Cancer Liquid Biopsy Market Report 2023-2029February 17, 2023 | marketwatch.comBreast Cancer Predictive Genetic Testing Market: Exploration of the Top Regions and Players with OpportunitiesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CGIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGIX CUSIPN/A CIKN/A Webwww.cancergenetics.com Phone(201) 479-1357FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.33 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,085,000Free FloatN/AMarket Cap$841,510.00 OptionableNot Optionable Beta2.72 Key ExecutivesJohn A. RobertsPresident, Chief Executive Officer & DirectorAndrew D. C. LaFrenceChief Operating & Financial OfficerRobert T. FremeauChief Scientific OfficerPing YehDirector & Chief Innovation OfficerRalf BrandtPresident-Discovery & Early Development ServicesKey CompetitorsTC BiopharmNASDAQ:TCBPG Medical InnovationsNASDAQ:GMVDBiodexa PharmaceuticalsNASDAQ:BDRXAltamira TherapeuticsNASDAQ:CYTOPear TherapeuticsNASDAQ:PEARView All Competitors CGIX Stock - Frequently Asked Questions How have CGIX shares performed in 2023? Cancer Genetics' stock was trading at $0.7025 at the start of the year. Since then, CGIX stock has decreased by 70.7% and is now trading at $0.2060. View the best growth stocks for 2023 here. What is Panna Sharma's approval rating as Cancer Genetics' CEO? 28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cancer Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD). What is Cancer Genetics' stock symbol? Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX." How do I buy shares of Cancer Genetics? Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cancer Genetics' stock price today? One share of CGIX stock can currently be purchased for approximately $0.21. How much money does Cancer Genetics make? Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $841,510.00 and generates $6.33 million in revenue each year. How can I contact Cancer Genetics? Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357. This page (NASDAQ:CGIX) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cancer Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.